Newsroom
Strive to Deliver Breakthroughs
HARBOUR GETS EX-CHINA RIGHTS TO KELUN'S ANTI-PD-L1 MAB
View moreHarbour BioMed to Develop Kelun-Biotech's Cancer Immunotherapy Candidate A167
View moreChina’s Harbour BioMed, Kelun ink a PD-L1 deal worth up to $350M
View moreHARBOUR GETS CHINESE RIGHTS TO HANALL'S BIOLOGICS
View moreHanAll Biopharma and Harbour BioMed Sign Collaboration and License Agreement to Develop Two Novel Biologic Therapies in Greater China
View moreHanAll Biopharma and Harbour BioMed Sign Collaboration and License Agreement to Develop Two Novel Biologic Therapies in Greater China
View moreStartup Harbour Biomed adds $50M in series A, snags antibody platform
View moreShanghai's Harbour BioMed Raises $50 Million; Acquires Discovery Company
View moreAdvantech Capital and Legend Capital-backed Harbour BioMed has invested in provider of transgenic mouse firm Harbour Antibodies.
View moreBankrolled by Chinese VCs, ex-Sanofi execs buy Cambridge antibody shop to create global immuno-oncology startup
View more